We are live on ! Find out more

Stoke Therapeutics

STOK

Market cap $1.91B

29.60 USD

+0.57

1.96%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

29.60

0.00

0%

1 day

1.96%

5 days

1.61%

1 month

-5.34%

3 months

-1.33%

6 months

-12.84%

Year to date

-4.21%

1 year

26.5%

5 years

23.69%

10 years

15.76%

About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Employees: 170

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 21.4%

Neutral 71.4%

Negative 7.1%

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare C.

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date.

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027 for zorevunersen. The advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study showcases the TANGO platform's broader therapeutic potential.

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Ann.

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission.

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha.

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

See News Rankings

Price charts implemented using Lightweight Charts™